511 related articles for article (PubMed ID: 35876118)
1. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
3. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
4. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
5. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
6. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
7. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
Mosca L; Navar AM; Wenger NK
J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
[TBL] [Abstract][Full Text] [Related]
8. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
10. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
11. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids.
Sabbour H; Bhatt DL; Elhenawi Y; Aljaberi A; Bennani L; Fiad T; Hasan K; Hashmani S; Hijazi RA; Khan Z; Shantouf R
Cardiovasc Drugs Ther; 2024 Feb; ():. PubMed ID: 38363478
[TBL] [Abstract][Full Text] [Related]
12. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
Huston J; Schaffner H; Cox A; Sperry A; Mcgee S; Lor P; Langley L; Skrable B; Ashchi M; Bisharat M; Gore A; Jones T; Sutton D; Sheikh-Ali M; Berner J; Goldfaden R
Am J Cardiovasc Drugs; 2023 Jul; 23(4):393-406. PubMed ID: 37188993
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
14. Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review.
Sutariya B; Montenegro DM; Chukwu M; Ehsan P; Aburumman RN; Muthanna SI; Menon SR; Vithani V; Penumetcha SS
Cureus; 2022 Dec; 14(12):e32346. PubMed ID: 36632258
[TBL] [Abstract][Full Text] [Related]
15. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
16. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
17. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Ito MK
Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
[TBL] [Abstract][Full Text] [Related]
18. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Szarek M; Bhatt DL; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Ketchum SB; Lira Pineda A; Doyle RT; Steg PG;
J Am Coll Cardiol; 2024 Apr; 83(16):1529-1539. PubMed ID: 38530686
[TBL] [Abstract][Full Text] [Related]
20. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
